This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Philip C. Roholt, MD
Alliance, Ohio

Arch Ophthalmol. 1987;105(9):1172.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Betaxolo hydrochloride, a β₁ adrenergic receptor blocking agent, has a low incidence of systemic effects and has been shown to be clinically safe and effective for the treatment of glaucoma.¹ However, a recent case report has documented respiratory problems with the use of topical betaxolo.² We wish to report a case of reduction in pulmonary capacity following the use of topical betaxolol, as well as the failure of systemic therapy to alleviate symptoms, in a patient with minimal reactive airway disease.

Report of a Case.

—A 71-year-old woman had pseudoexfoliative glaucoma of the right eye. Ocular tensions in this eye ranged from 25 to 30 mm Hg. The optic disc had a cup-to-disc ratio of 0.9. A superior paracentral scotoma was present in the right eye. The left eye had a normal intraocular pressure, cup-to-disc ratio, and visual field. She was allergic to pilocarpine . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?